Exciva
Edit

Exciva

http://www.exciva.com/
Last activity: 10.07.2026
Active
Categories: AlzheimersAlzheimer'sBiotechClinicalTrialsCNSHealthcareNeurologyNeurosciencePharmaPharmaceuticalsTherapeutics
Exciva is a clinical stage biopharmaceutical company focused on delivering an innovative treatment to address symptoms of Alzheimer’s patients.
Mentions
16
Location: Germany
Total raised: $128.34M
Email

Investors 3

Funding Rounds 3

DateSeriesAmountInvestors
10.07.2026Series B$58.24M-
20.01.2026Series B$59.64MAndera Par...
27.10.2021Series A$10.46M-

Mentions in press and media 16

DateTitleDescription
10.07.2026Exciva raises €51 million ($59m) in Series B funding roundExciva GmbH, a biopharmaceutical company developing novel therapeutic compounds for the treatment of neuropsychiatric conditions, today announces the closing of a €51 million ($59m) Series B financing round. Gimv and EQT Life Sciences co-le...
10.07.2026Exciva appoints distinguished biopharma leaderMark Altmeyer as chairman of the boardStrategic appointment underscores Exciva’s ambition to advance Deraphan, its lead product to treat agitation in Alzheimer’s patients, through late-stage development and global expansion Exciva GmbH, a biopharmaceutical company developing no...
10.07.2026Exciva doses first patient in Phase 2/3 trial of Deraphan for agitation in Alzheimer’s disease and extends Series B roundSERENADA trial to run at up to 60 sites across US, UK, Canada and Europe, targeting 300 patients Exciva brings Series B round to €53M, with Dolby Ventures joining investor pool, and strengthens management with appointment of seasoned COO Ex...
07.05.2026Family office deal-making rebounds in April with healthcare betsFamily offices stepped up their deal-making in April after a slowdown in March amid the Iran war. Nearly a third of April’s investments were made in healthcare or life sciences startups, per data firm Fintrx. Laurene Powell Jobs’ Emerson Co...
22.01.2026Exciva Secures €51 Million Series B: Alzheimer's Agitation Therapy Advances to Phase 2Exciva closed a €51 million Series B funding round. This financing fuels Deraphan, its Alzheimer's agitation therapy, into crucial Phase 2 trials. EQT Life Sciences and Gimv spearheaded the investment. The global study addresses a pressing ...
20.01.2026Exciva: €51 Million Series B Closed To Advance Alzheimer’s Agitation Therapy Into Phase 2EQT Life Sciences announced it co-led a €51 million Series B financing in Exciva, a clinical-stage biopharmaceutical company developing treatments for behavioral symptoms associated with Alzheimer’s disease, with proceeds earmarked to move ...
20.01.2026Andera Partners’ Portfolio Company Exciva Secures €51 Million Series B to Advance Clinical Program for Alzheimer’s-Related Agitation.Andera Partners, a leading European private equity player, today announced that it participated in the €51 million ($59 million) Series B financing round of its portfolio company Exciva GmbH, a biopharmaceutical company developing novel the...
20.01.2026German BioTech Exciva lands €51 million to advance Alzheimer’s drug testing in patientsHeidelberg-based Exciva, a biopharmaceutical company developing novel therapeutic compounds for the treatment of neuropsychiatric conditions, today announces the closing of a €51 million ($59 million) Series B round. Gimv and EQT Life Scien...
20.01.2026Exciva raises €51M in Series B FundingExciva, a Heidelberg, Germany-based biopharmaceutical company developing new therapeutic compounds for the treatment of neuropsychiatric conditions, raised €51M in Series B funding. The round was led by Gimv and EQT Life Sciences. Additiona...
20.01.2026EQT Life Sciences co-leads EUR 51 million Series B in Exciva to advance its Alzheimer’s therapy into clinical Phase 2EQT Life Sciences co-leads EUR 51 million Series B in Exciva to advance its Alzheimer’s therapy into clinical Phase 2 Tue, Jan 20, 2026 07:30 CET Report this content Series B financing will support Exciva’s Phase 2 clinical trial of its lea...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In